Kazia Therapeutics (KZIA) CFO James Levine Buys 200,000 Shares

On June 19, 2026, James Levine, the Chief Financial Officer of Kazia Therapeutics Limited, purchased 200,000 shares of the company. This transaction was not part of a pre-arranged trading plan, showing Levine's active investment in the company he helps lead.

Insider Buying and Selling at Kazia Therapeutics Limited

Kazia Therapeutics saw insider activity with James Levine, its CFO, acquiring 200,000 shares. This purchase wasn't under a Rule 10b5-1 plan, suggesting a direct vote of confidence in the company's prospects. Additionally, Sudha Rao, the Chief Scientific Officer, also bought 250,000 shares on the same day.

Other Institutional Activity in Kazia Therapeutics

Several institutional investors have also shown interest in Kazia Therapeutics. Bleichroeder LP held its position steady at 400,000 shares, worth about $2.98 million. Stonepine Capital Management, LLC, however, reduced its stake by 115,180 shares, now holding 345,179 shares valued at approximately $2.57 million, marking a 25% decrease. Point72 Asset Management, L.P. maintained its position with 200,000 shares valued at $1.49 million. Balyasny Asset Management L.P. and FLPutnam Investment Management Co both opened new positions, holding 193,114 shares and 142,469 shares, respectively, valued at $1.44 million and $1.06 million.

Kazia Therapeutics Limited Stock Up 41.4%

Shares of NasdaqCM:KZIA traded near $14.69 on Wednesday. Kazia Therapeutics has a market cap of approximately $160 million. Although the company is not currently profitable, it has a forward P/E ratio of -914.55, reflecting its status as a biotech firm with significant research and development costs. The stock's beta is 2.181, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from a low of $4.86 to a high of $17.4, with a 50-day moving average of $12.29 and a 200-day moving average of $8.91.

Analysts Set New Price Targets

On June 11, 2026, Lake Street initiated coverage of Kazia Therapeutics with a buy rating and a price target of $32. Earlier, Laidlaw & Co. had also initiated a buy rating with a target of $25 on April 15, 2026. HC Wainwright & Co. reiterated their buy rating, setting an $18 target on January 28, 2026. Overall, the consensus among analysts is a strong buy, with a mean target price of $25.78 based on four analyst opinions.

About Kazia Therapeutics

Kazia Therapeutics Limited is a biotechnology company based in Sydney, Australia, focusing on oncology. Its main product, paxalisib, is in advanced clinical trials for treating various brain cancers. Additionally, Kazia is developing EVT801 for solid tumors and ovarian cancer. The company collaborates with several research institutions and pharmaceutical firms, underscoring its commitment to cancer treatment innovation.

Bottom Line

James Levine's recent purchase of Kazia Therapeutics shares highlights his confidence in the company's direction. While insider transactions can indicate potential, investors should remember that these filings are historical and may not reflect current positions. Kazia's focus on cancer therapies and its collaborations make it a company to watch in the biotech sector.